Native Mass Spectrometry as a Drug Discovery Engine

Published

April 7, 2022

Native Mass Spectrometry as a Drug Discovery Engine

Using mass spectrometry to characterise and screen large intact protein targets, captured directly in their native state, is making waves as a differentiated approach to hit finding in drug discovery, explains Dr Jonathan T.S. Hopper, founder and VP of Platforms at OMass Therapeutics…

MORERelated News
Native mass spectrometry: Drug discovery’s new kid on the block
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s...
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...